— Know what they know.
Not Investment Advice

STSA NASDAQ

Satsuma Pharmaceuticals, Inc.
1W: +4.8% 1M: +1.9% 3M: +24.0% 1Y: -67.7% 3Y: -95.9%
$1.10
Last traded 2023-06-07 — delisted
NASDAQ · Healthcare · Biotechnology · $36.5M mcap · 15M float · 7.96% daily turnover

Cash Flow Trends

Operating Cash Flow
-$52M -19.8% ▼
Capital Expenditures
$472K +76.7% ▲
5Y CAGR: +52.1%
Free Cash Flow
-$52M -15.5% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$594K +102.9% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2018FY2019FY2020FY2021FY2022
— Operating Activities —
Net Income-$7M-$28M-$48M-$51M-$70M
Depreciation & Amort.$57K$141K$239K$393K$683K
Stock-Based Comp.$170K$747K$4M$5M$6M
Change in Working Capital$295K-$2M$794K$1M$367K
Other Non-Cash Items-$157K$132K$102K$48K$12M
Operating Cash Flow-$7M-$30M-$42M-$43M-$52M
— Investing Activities —
Capital Expenditures-$402K-$551K-$5M-$2M-$472K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0-$100M-$34M-$89M-$48M
Investment Sales$0$5M$97M$40M$92M
Other Investing$0$0$0$0$0
Investing Cash Flow-$402K-$96M$58M-$51M$43M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$11M$143M-$2M$73M$9M
Financing Cash Flow$11M$143M-$2M$73M$9M
Net Change in Cash$4M$18M$14M-$20M$594K
Cash End of Period$5M$23M$36M$16M$16M
Free Cash Flow-$7M-$30M-$47M-$45M-$52M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms